SUGGESTED FORMULATION. Lot Number. Expiry Date. Ingredient Listing Qty. Unit NDC # Supplier

Similar documents
Ingredient Listing Qty. Unit NDC # Supplier ml

Lidocaine Hydrochloride 2%, Metronidazole 2%, Misoprostol % Topical Ointment (Suspension, 30 g) Ingredient Listing Qty. Unit NDC # Supplier

Ingredient Listing Qty. Unit NDC # Supplier. Sterile Preparation

Ingredient Listing Qty. Unit NDC # Supplier TBD. Sterile Preparation

Ingredient Listing Qty. Unit NDC # Supplier. Sterile Preparation

Hydrocortisone 2%, Hydroquinone 6%, Kojic Acid 4%, Salicylic Acid 4%, Tretinoin 0.01% Topical Gel (Suspension, 20 g)

Ingredient Listing Qty. Unit NDC # Supplier

Ingredient Listing Qty. Unit NDC # Supplier g. Sterile Preparation

Ingredient Listing Qty. Unit NDC # Supplier. Sterile Preparation

Ingredient Listing Qty. Unit NDC # Supplier. q.s. to ml

Methimazole 5 mg Oral Chewable Treats (Solid Suspension, 60 x 1 ml Treats) FIN F v2. Ingredient Listing Qty. Unit NDC # Supplier

Ingredient Listing Qty. Unit NDC # Supplier g

Fluoxetine Hydrochloride 5.6 mg Oral Chewable Treats (Solid Suspension, 60 x 1 ml Chewable Treats)

Ingredient Listing Qty. Unit NDC # Supplier

905 UNIFORMITY OF DOSAGE UNITS

Disclosure. Objectives. Objectives. Introduction. Introduction. Non-Sterile Compounding/Calculations

247 CMR BOARD OF REGISTRATION IN PHARMACY

LubriTose Mannitol Michael Crowley, Director of R&D, Excipients

The Therapeutic Goods Act (1989)

Q&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution)

Residual Solvents: FDA/ Regulatory Perspective

History Note: Authority G.S ; ; ; Eff. May 1, 1997; Amended Eff. January 1, 2015; March 1, 2013.

Stability Study of Hydralazine HCl Oral Solutions Compounded in Humco Oral Vehicles to Determine a Beyond-use Date

LIQUID PREPARATIONS FOR ORAL USE. Final text for addition to The International Pharmacopoeia (November 2007)

Model Standards for Pharmacy Compounding of Non-Sterile Preparations

The Pharmacy Board of Australia s

Student Practical Guide (1) Milk of Magnesia

Guidance for Pharmacists on Extemporaneous Dispensing

Preparation of TAMIFLU for Oral Suspension. Emergency Compounding of an Oral Suspension from TAMIFLU Capsules (Final Concentration 15 mg/ml)

Food Fortification Regulations, 2016 (Gazetted on 24 October, 2016) ARRANGEMENT OF SECTIONS PART I PRELIMINARY

Vol. 41(1) [Jan. Feb. 2015] (P) \\uspnetapp2\share\share\uspnf\printq\pager\xmlin\lyc_ _m99989.xml. Nov.

STANDARDS FOR PHARMACY COMPOUNDING OF NON-STERILE PREPARATIONS

SAFETY DATA SHEET. Oxycodone Hydrochloride (CII) Capsule, 5mg, 100 count bottle NDC

SLEEP AIDS - LABELLING STANDARD

6/7/2017 CHANGES IN PHARMA REGULATIONS HOW IT AFFECTS THE OR NURSE DISCLOSURE OBJECTIVES

Food supplement manufacture

INTERNATIONAL PHARMACOPOEIA MONOGRAPH ON LIQUID PREPARATIONS FOR ORAL USE

Stability of Captopril in an Extemporaneously Compounded Humco s Oral Products

ANTACID LABELLING STANDARD

Ingredients adapted to a fit for use model. APIs allowed the fit for use strategy to work. There has been a shift to designed for purpose

Technical Monograph n 17, 2nd Edition. Guidelines for Specifying the Shelf Life of Plant Protection Products

If you have any concerns about taking this medicine, ask your doctor or pharmacist.

Compounding Medication Regulations

Apo-Ciclopirox ciclopirox USP 8% w/w Nail Lacquer (Topical Solution)

DRUG PRODUCT PERFORMANCE: CONSIDERATIONS FOR INTERCHANGEABILITY OF MULTISOURCE DRUG SUBSTANCES AND DRUG PRODUCTS

ANIMAL HEALTH DIVISION. Technologies & Services

STABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS

Chapter 8. Nonsterile Pharmaceutical Compounding. Paradigm Publishing, Inc. 1

Change to read: BRIEFING

A. General Appearance

MATERIAL SAFETY DATA SHEET

Pharmaceutical Calculations

Stability Of Extemporaneously Prepared Oral Liquid Formulations Part XI

Assessment of Low Dose Content Uniformity of Indomethacin in Excipient Blends Using FT-Raman Mapping Spectroscopy

Drugs with Handling Concerns Due to Reproductive Risk

USP Perspective on Atypical Actives November 29, 2017

CARD/MAIL/PRE-APPROVAL/PREFERRED RIDER FOR PRESCRIPTION DRUG [INSURANCE] [Policy]holder: Group Policy No: Effective Date:

H 7816 S T A T E O F R H O D E I S L A N D

OCE TABLETING DIRECT COMPRESSION CO-PROCESSED LACTOSE. Technical brochure MicroceLac 100

DRAFT PROPOSAL FOR REVISION OF GENERAL MONOGRAPHS: PARENTERAL PREPARATIONS. (July 2012) Draft for comment

BRIEFING. Nonharmonized attributes: Identification, Heavy metals, Characters, Labeling, Bacterial endotoxins, Sterility, Storage.

General Concepts in the European Pharmacopoeia. Anne-Sophie Bouin European Pharmacopoeia Department, EDQM, Council of Europe

Commercial Bulleting Aloe Flakes

COMMENTS. Submitted by The International Pharmaceutical Aerosol Consortium

US A United States Patent (19) 11 Patent Number: 5,635,209 Groenewoud et al. 45 Date of Patent: Jun. 3, 1997

Draft Guidance for Pharmacists on Extemporaneous Dispensing. Version 1

LABELING - SKIN OF PRODUCT Arun. N 1 Kadibagil vinay R 2 Ganti basavaraj Y 3 PG Scholar,

NEPHROCHECK Calibration Verification Kit Package Insert

Rebaudioside a From Multiple Gene Donors Expressed in Yarrowia Lipolytica

Practical 3 Extemporaneous Preparations Solutions. Name: Group: Date:

STERI-PEROX. Technical Data File. 3% & 6% Hydrogen Peroxide Solution VL Rev. 20 January 2012

SUBJECT: Effective Date: Policy Number: Controlled Substance and Prescription Drugs 11/30/

Available Online through Research Article

TENOFOVIR TABLETS: Final text for addition to The International Pharmacopoeia (June 2010)

1 INJECTIONS INTRODUCTION

Development of USP Delayed Release Aspirin Tablets using Opadry Enteric, Acrylic-Based Coating System

Town and Country Compounding and Consultation Services, LLC 10/17/17

Prime Asthma Relief Refill NDC

HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) DRAFT (12/08) POINTS TO CONSIDER ON STABILITY TESTING OF HOMEOPATHIC MEDICINAL PRODUCTS

This letter is to notify you of recent changes to the TAMIFLU product monograph. Please note, additions/changes have been highlighted in yellow.

Stability of levetiracetam oral solution repackaged in oral plastic syringes

Template Standard Operating Procedure For: Handling of Midazolam and other controlled drugs in Dental Practices

Title 17-A: MAINE CRIMINAL CODE

S e c u n d u m A r t e m

Test Bank for Basic Pharmacology for Nurses 14th edition by Clayton, Stock and Harroun

REVISION OF MONOGRAPH ON TABLETS. Tablets

Medicines. Let s Talk About. health literacy. wisconsin. A division of Wisconsin Literacy, Inc.

REGULATORY REQUIREMENTS FOR REGISTRATION OF HEALTH SUPPLEMENTS IN MALAYSIA

MATERIAL SAFETY DATA SHEET

$250 (Deductible does not apply to Tier 1 and Tier 2) $500 (Deductible does not apply to Tier 1 and Tier 2)

Laboratory Pesticide Formulations, Labels, and Safety

RULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER DRUG DONATION REPOSITORY PROGRAM TABLE OF CONTENTS

NEPHROCHECK Liquid Control Kit Package Insert

Prescribing and Dispensing Drugs

Summary Public Assessment Report. Generics. Pregabalina Biofarmoz PT/H/1292/ /DC

AgraQuant F.A.S.T. Casein Sandwich ELISA

RealLine HIV quantitative Str-Format

KEYWAX WX1014 RUBBER WAX CONCENTRATE

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS

Perform extraction for finished product, rinse water or swab. Transfer 12 drops of extract to incubation vial.

Transcription:

9/17/2016; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Aloe Vera (Powder) (Freeze Dried) 0.200 g Tacrolimus 5% Stock Powder Blend 0.600 g Ethoxy Diglycol 1.0 ml Medisca U-Mild Shampoo Base 70.0 ml Purified Water, USP q.s. to 100.0 ml Lot Number Expiry Date Tacrolimus 5% Stock Powder Blend Tacrolimus, USP TBD Lactose (Monohydrate), NF q.s. to 2.00 g SPECIAL PREPARATORY CONSIDERATIONS Ingredient-Specific Information Light sensitive (protect from light whenever possible): Aloe Vera, Tacrolimus Hygroscopic (protect from moisture whenever possible): Aloe Vera, Ethoxy Diglycol Heat sensitive (protect from heat whenever possible): Narrow Therapeutic Index Tacrolimus Tacrolimus Preparatory Guidelines Non-Sterile Preparation Sterile Preparation Processing Error / Testing Considerations: Special Instruction: To account for processing error considerations during preparation, it is suggested to measure an additional 5 to 9% of the required quantities of ingredients. Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn. Tacrolimus has a Narrow Therapeutic Index. This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.

9/17/2016; Page 2 SUGGESTED PREPARATION (for 100 ml) Weigh and / or measure the following ingredients when appropriate: Ingredient Listing Qty. Unit Multiplication factor (*) : Processing Error Qty. to measure Aloe Vera (Powder) (Freeze Dried) 0.200 g Tacrolimus 5% Stock Powder Blend 0.600 g Ethoxy Diglycol 1.0 ml Medisca U-Mild Shampoo Base 70.0 ml Purified Water, USP q.s. to 100.0 ml Tacrolimus 5% Stock Powder Blend Tacrolimus, USP TBD --- --- Lactose (Monohydrate), NF q.s. to 2.00 g --- --- Weigh / measure just prior to use. * Takes into account increased batch size conversions and density conversions, if required.

9/17/2016; Page 3 1. Ingredient quantification: Preparatory Instruction A. Determine the potency of Tacrolimus based on the certificate of analysis: 100% MINUS Water Content (from certificate of analysis) % DIVIDED BY 100 EQUALS Quantity of water free Tacrolimus, in decimal MULTIPLIED BY Assay on anhydrous basis result (from certificate of analysis) % DIVIDED BY 100 EQUALS i. Potency of Tacrolimus, in decimal 2. Ingredient quantification: A. Determine the quantity (in g) of Tacrolimus to make a Tacrolimus 5% Stock Powder Blend, batch size (2 g): Quantity of Tacrolimus required for 2 g 0.100 g DIVIDED BY Potency of Tacrolimus, in decimal (Step 1Ai) EQUALS i. Quantity of Tacrolimus needed for 2 g g

9/17/2016; Page 4 3. Tacrolimus 5% Stock Powder Blend preparation: A. By geometric addition, combine and triturate the following ingredients together to form a fine, homogeneous powder blend: -Tacrolimus (amount determined in Step 2Ai) -Lactose (Monohydrate) (q.s. to 2.00 g) 4. Powder-liquid preparation: A. By geometric addition, combine and mix the following ingredients together to form a homogeneous powder blend: -Tacrolimus 5% Stock Powder Blend (0.600 g plus processing error adjustment) -Aloe Vera (Powder) (Freeze Dried) B. Levigate the homogeneous powder blend (Step 4A) with the Ethoxy Diglycol. End result: Homogeneous paste-like dispersion. 5. Medium preparation: A. Incrementally add the homogeneous paste-like dispersion (Step 4B) to the U-Mild Shampoo Base. Specifications: Continuously mix until all solid particles have completely dissolved. End result: Homogeneous liquid-like solution. 6. Filling to volume: A. Add Purified Water to the mixture (Step 5A) to fill to the required batch size (100.0 ml plus processing error adjustments). Specifications: Continuously mix until homogeneous. End result: Homogeneous liquid-like solution. 7. Product transfer: Transfer the final product into the specified dispensing container (see Packaging Requirements ).

9/17/2016; Page 5 SUGGESTED PRESENTATION Estimated Beyond-Use Date 1 30 days, as per USP. Packaging Requirements Use as directed. Do not exceed prescribed dose. - Tightly closed, light-resistant topical dispensing bottle. - To be administered with a metered-dose measuring device. 6 Cap tightly after use. 2 Keep out of reach of children. 7 Protect from light. Auxiliary Labels 3 Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use. 8 For external use only. 4 Keep at room temperature (20 C 23 C). 9 Keep in a dry place. 5 May impair mental and/or physical ability. Use care when operating a car or machinery. 10 Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants. Pharmacist Instructions Add any auxiliary labels specific to the API to the dispensing container as deemed necessary. Patient Instructions Contact your pharmacist in the event of adverse reactions. IMPORTANT: The quantity of API administered is directly dependent on the quantity of product applied.

9/17/2016; Page 6 REFERENCES 1. Cosmetics for special populations and for use as vehicles. In: Allen, LV, Jr. The Art, Science and Technology of Pharmaceutical Compounding Fourth Edition. American Pharmaceutical Association; 2012: 441. 2. Aloe Vera. In: Sweetman SC, ed. Martindale: The Complete Drug Reference, 36th Edition. London, England: The Pharmaceutical Press; 2009: 1588. 3. Tacrolimus. In: Sweetman SC, ed. Martindale: The Complete Drug Reference, 36 th Edition. London, England: The Pharmaceutical Press; 2009: 1843. 4. Aloe (Monograph). In: O Neil MJ. The Merck Index 15th Edition. Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #299. 5. Tacrolimus (Monograph). In: O Neil MJ. The Merck Index 15 th Edition. Whitehouse Station, NJ: Merck & Co, Inc.; 2013: #9155. 6. Aloe. In: Trissel LA. Trissel s Stability of Compounded Formulations, 5th Edition. American Pharmaceutical Association; 2012: 21. 7. Tacrolimus. In: Trissel LA. Trissel s Stability of Compounded Formulations, 5 th Edition. American Pharmaceutical Association; 2012: 456. 8. Aloe (Monograph). United States Pharmacopeia XXXIX / National Formulary 34. Rockville, MD. US Pharmacopeial Convention, Inc. 2016: 2385. 9. Tacrolimus (Monograph). United States Pharmacopeia XXXIX / National Formulary 34. Rockville, MD. US Pharmacopeial Convention, Inc. 2016: 5983. 10. USP <795>. United States Pharmacopeia XXXIX / National Formulary 34. Rockville, MD. US Pharmacopeial Convention, Inc. 2016: 617. DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.